Reneo Pharmaceuticals Stock Quote RPHM - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.67

Bid

1.65

Ask

1.80

Volume

115,223

1.66 Day's Range 1.7096

0.9801 52 Week Range 10.98

Market Cap

55.631M

Previous Close

1.65

Open

1.66

Last Trade

146

1.67

(formt)

Last Trade Time

Financial Volume

$ 192,995

VWAP

1.675

Average Volume (3m)

184,339

Shares Outstanding

33,311,787

Dividend Yield

PE Ratio

-0.72

Earnings Per Share (EPS)

-2.32

Revenue

Net Profit

-77.39M

Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing ... Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

reneopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Reneo Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RPHM. The last closing price for Reneo Pharmaceuticals was $1.65. Over the last year, Reneo Pharmaceuticals shares have traded in a share price range of $ 0.9801 to $ 10.98.

Reneo Pharmaceuticals currently has 33,311,787 shares outstanding. The market capitalization of Reneo Pharmaceuticals is $55.63 million. Reneo Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.72.

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.05	-2.90697674419	1.72	1.76	1.62	120196	1.68469105	CS
4	0.02	1.21212121212	1.65	1.92	1.62	106098	1.70858927	CS
12	0.04	2.45398773006	1.63	1.92	1.55	184339	1.65506317	CS
26	-6.355	-79.1900311526	8.025	8.29	0.9801	630295	2.06537561	CS
52	-7.47	-81.7286652079	9.14	10.98	0.9801	393151	3.18272977	CS
156	-11.36	-87.1834228703	13.03	14.95	0.9801	170536	3.82797524	CS
260	-13.63	-89.0849673203	15.3	16.83	0.9801	170612	3.96778802	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M